On the one hand, the possible mechanism is that lenvatinib can inhibit IFN-γ signal transduction in tumor cells by targeting FGFR, and the combination of PD-1 and lenvatinib can reverse the immunosuppressive state of the tumor microenvironment, thus improving the immune response rate of PD-1 inhibitors (12, 30). The gene discussed is PDCD1; the disease is neoplasm.